Circadian boosts neuroscience investment
09 October, 2003 by Tanya HollisCircadian Technologies (ASX:CIR) has added another string to its neuroscience bow with an investment in new Melbourne research.
Feds let CSL supply deal lapse
04 September, 2003 by Melissa TrudingerThe federal government made a decision more than a year ago not to take up an option to extend its contract with CSL for the supply of blood plasma products to Australian hospitals for another five years.
Ross River study offers arthritis clues
28 August, 2003 by Graeme O'NeillHundreds of Australians have endured misery and debilitating arthritic pain in the joints after being infected by mosquito-borne Ross River Virus. The symptoms can last for months, and recovered patients can relapse years later.
New neuro facility establishes clincial trials program
14 August, 2003 by Melissa TrudingerA clinical trials program for neuroscience is being established as a platform by the National Neuroscience Facility (NNF) to encourage greater involvement of Australian neuroscience researchers and clinicians in industry-sponsored and investigator driven clinical studies.
$42.5m neuroscience facility opens
13 August, 2003 by Melissa TrudingerBrain and mind disorders, watch out -- Australia's neuroscience researchers are coming after you.
National Neuroscience Facility opens for business
08 August, 2003 by Melissa TrudingerCooperative competition -- or 'coopetition' -- was the name of the game last night at the launch of the AUD$18 million National Neuroscience Facility in Melbourne.
US paper man boosts Genesis NZ
07 August, 2003 by Jeremy TorrNew Zealand biotech Genesis Research and Development has successfully lured an ex-US heavyweight to head up its increased push into the plant biotech arena.
Trounson hasn't resigned: NSCC
05 August, 2003 by Iain ScottProf Alan Trounson has not resigned from the National Stem Cell Centre, contrary to a report in today's The Australian newspaper.
NZ firm Virionyx hits rich research vein
04 August, 2003 by Jeremy TorrNew Zealand biotech Virionyx has hit a rich vein with a development deal for a frontline therapy suitable for a range of high-level infections such as AIDS, SARS, West Nile virus and dengue fever -- plus bioterrorism threats.
Chemeq announces $7m loss
28 July, 2003 by Jeremy TorrWA antimicrobial vet biotech Chemeq (ASX: CMQ) has listed a AUD$7.2 million loss for the 2002-03 fiscal year, described as "in line with the company's budget" despite a recent $25 million injection from share placements.
Fundraising activity nets $8m for Stem Cell Sciences
25 July, 2003 by Melissa TrudingerMelbourne company Stem Cell Sciences has emerged from recent capital-raising activities AUD$8 million better off.
NSCC looks towards global stage
23 July, 2003 by Melissa TrudingerProf Alan Trounson is stepping away from his role as CEO of the National Stem Cell Centre (NSCC) to become its Global Science Strategic Advisor, with a focus on expanding the centre's international relationships and influence.
'Artistic' rat cells could shed light on learning
11 July, 2003 by Jeremy TorrAustralian and US researchers have combined efforts to produce artistic rat cells, which can paint pictures across the world from their Petri dish. And hopefully give some insight into the learning process at the same time.
Germline therapy tipped for longer life
09 July, 2003 by Graeme O'NeillEvolution doesn't care what happens to the body after reproduction, says Prof Miroslav Radman, so we humans should consider taking out little extra cellular life insurance to ward off cancer in our twilight years.
New study points to possible 'flu firewall'
27 May, 2003 by Graeme O'NeillAn Australian-US study has shown it may be possible to develop a 'firewall' vaccine against the world's most dangerous human pathogen, the influenza virus.
